Brief Description
Cantena Biosciences uncovered a novel protein conjugation method that can bring breakthroughs in biological therapeutics, autoimmune disorders, and vaccine development.
Catena’s technology allows the attachment of any two proteins together faster and more selectively than any competing method by attaching the natural amino acids tyrosine and cysteine. Since the company's platform uses only naturally occurring amino acids, it is more widely applicable than competing technologies and can be used to create complicated constructs far beyond the capability of genetic fusions or chemical attachment found in the industry today.
Inventors
Jennifer Doudna, Christof Fellmann, Matthew Francis, Marco Jackson Lobba, Alan Michael Marmelstein, Johnathan Maza, Casey Mogilevsky